Literature DB >> 12702500

Transcription activation function of C/EBPalpha is required for induction of granulocytic differentiation.

Karen Keeshan1, Giorgia Santilli, Francesca Corradini, Danilo Perrotti, Bruno Calabretta.   

Abstract

The CCAAT/enhancer binding protein-alpha (C/EBPalpha) is a transcription factor required for differentiation of myeloid progenitors. In addition to specific DNA binding, C/EBPalpha is also involved in protein-protein interactions, some of which (p21, Cdk2/Cdk4, E2F) appear to be required for inhibition of proliferation and possibly differentiation. To investigate the mechanisms of C/EBPalpha-induced granulocytic differentiation, we generated C/EBPalpha mutants reportedly defective in DNA binding, transactivation, and Cdk2/Cdk4 and E2F interaction and assessed their effects in a myeloid precursor cell line, primary bone marrow and C/EBPalpha knockout fetal liver precursor cells. We show here that the DNA binding-deficient Lys298Glu mutant, the E2F binding-deficient basic region mutant 2 (BRM-2) carrying the Ile294Ala and Arg297Ala substitutions, and the transactivation-deficient N-terminus truncated p30 mutant all fail to promote differentiation on ectopic expression in myeloid precursor cells. By contrast, ectopic expression of the Cdk2/Cdk4 interaction-deficient Delta177-191 mutant promotes differentiation and induces gene expression as effectively as wild-type C/EBPalpha. Thus, the integrity of the transactivation and DNA binding domains, but not of the Cdk2/Cdk4 interaction region, is necessary for C/EBPalpha-induced differentiation. Since the E2F binding-deficient BRM-2 mutant interacted with E2F-1 but failed to activate gene expression, our results lend support to the hypothesis that activation of gene transcription is the determining factor in C/EBPalpha-dependent differentiation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12702500     DOI: 10.1182/blood-2003-02-0477

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  38 in total

1.  Expression of the transcriptional repressor Gfi-1 is regulated by C/EBP{alpha} and is involved in its proliferation and colony formation-inhibitory effects in p210BCR/ABL-expressing cells.

Authors:  Maria Rosa Lidonnici; Alessandra Audia; Angela Rachele Soliera; Marco Prisco; Giovanna Ferrari-Amorotti; Todd Waldron; Nick Donato; Ying Zhang; Robert V Martinez; Tessa L Holyoake; Bruno Calabretta
Journal:  Cancer Res       Date:  2010-10-05       Impact factor: 12.701

2.  Repression of transcriptional activity of C/EBPalpha by E2F-dimerization partner complexes.

Authors:  Katrin Zaragoza; Valérie Bégay; Anja Schuetz; Udo Heinemann; Achim Leutz
Journal:  Mol Cell Biol       Date:  2010-02-22       Impact factor: 4.272

3.  Regulation of apoptotic and growth inhibitory activities of C/EBPalpha in different cell lines.

Authors:  Guo-Li Wang; Xiurong Shi; Elizabeth Salisbury; Nikolai A Timchenko
Journal:  Exp Cell Res       Date:  2008-02-13       Impact factor: 3.905

4.  Inducible activation of CEBPB, a gene negatively regulated by BCR/ABL, inhibits proliferation and promotes differentiation of BCR/ABL-expressing cells.

Authors:  Clara Guerzoni; Michela Bardini; Samanta A Mariani; Giovanna Ferrari-Amorotti; Paolo Neviani; Maria Luisa Panno; Ying Zhang; Robert Martinez; Danilo Perrotti; Bruno Calabretta
Journal:  Blood       Date:  2006-01-17       Impact factor: 22.113

5.  Phosphorylation of serine 21 modulates the proliferation inhibitory more than the differentiation inducing effects of C/EBPα in K562 cells.

Authors:  Valentina Fragliasso; Yuri Chiodo; Giovanna Ferrari-Amorotti; Angela Rachele Soliera; Gloria Manzotti; Sara Cattelani; Olivia Candini; Giulia Grisendi; Jenny Vergalli; Samanta Antonella Mariani; Clara Guerzoni; Bruno Calabretta
Journal:  J Cell Biochem       Date:  2012-05       Impact factor: 4.429

6.  miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts.

Authors:  Anna M Eiring; Jason G Harb; Paolo Neviani; Christopher Garton; Joshua J Oaks; Riccardo Spizzo; Shujun Liu; Sebastian Schwind; Ramasamy Santhanam; Christopher J Hickey; Heiko Becker; Jason C Chandler; Raul Andino; Jorge Cortes; Peter Hokland; Claudia S Huettner; Ravi Bhatia; Denis C Roy; Stephen A Liebhaber; Michael A Caligiuri; Guido Marcucci; Ramiro Garzon; Carlo M Croce; George A Calin; Danilo Perrotti
Journal:  Cell       Date:  2010-03-05       Impact factor: 41.582

7.  CCAAT/enhancer binding proteins alpha and epsilon cooperate with all-trans retinoic acid in therapy but differ in their antileukemic activities.

Authors:  Young-Jin Lee; Letetia C Jones; Nikolai A Timchenko; Danilo Perrotti; Daniel G Tenen; Scott C Kogan
Journal:  Blood       Date:  2006-06-20       Impact factor: 22.113

8.  Identification of gene targets of mutant C/EBPα reveals a critical role for MSI2 in CEBPA-mutated AML.

Authors:  Elizabeth Heyes; Luisa Schmidt; Gabriele Manhart; Thomas Eder; Ludovica Proietti; Florian Grebien
Journal:  Leukemia       Date:  2021-02-23       Impact factor: 11.528

9.  High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2 dependent suppression of C/EBPalpha-driven myeloid differentiation.

Authors:  Ji Suk Chang; Ramasamy Santhanam; Rossana Trotta; Paolo Neviani; Anna M Eiring; Edward Briercheck; Mattia Ronchetti; Denis C Roy; Bruno Calabretta; Michael A Caligiuri; Danilo Perrotti
Journal:  Blood       Date:  2007-05-02       Impact factor: 22.113

10.  Liver tumors escape negative control of proliferation via PI3K/Akt-mediated block of C/EBP alpha growth inhibitory activity.

Authors:  Guo-Li Wang; Polina Iakova; Margie Wilde; Samir Awad; Nikolai A Timchenko
Journal:  Genes Dev       Date:  2004-04-15       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.